NDASUBCUTANEOUSSOLUTION
Approved
Oct 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
LASIX ONYU (furosemide) by Innovation Pharmaceuticals is 12. First approved in 2025.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LASIX ONYU is a subcutaneous formulation of furosemide, a loop diuretic that inhibits sodium and chloride reabsorption in the proximal and distal tubules and loop of Henle to produce diuresis. It is indicated for heart failure (NYHA Class II and III) where it delivers comparable efficacy to intravenous dosing via subcutaneous infusion over 5 hours. The subcutaneous route offers a novel delivery mechanism for a well-established diuretic class, enabling patient-controlled or home-based administration.
Launch15.2 years to LOE
Early-stage launch product with significant opportunity to build market share in heart failure diuretic management, likely requiring substantial field and medical affairs investment.
Mechanism of Action
12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory…
Worked on LASIX ONYU at Innovation Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.